

TO-THE-POINT



A Vaccine Provider Newsletter from the Barry-Eaton District Health Department

HPV VACCINE SERIES COMPLETION FOR ADOLESCENTS

Protect your patients from cervical cancer, and the many other HPV-related cancers affecting men and women, by recommending, promoting, and offering the HPV vaccine.

Join the [Michigan Cancer Consortium](#) (MCC) and Barry Eaton District Health Department’s focus on prevention in 2024 and increase the proportion of adolescents ages 13-17 years who have completed the Human Papilloma Virus (HPV) vaccine series.

HPV vaccines exhibit a high efficacy among persons without evidence of prior infection, thus the significance of completing the vaccination series prior to exposure to HPV.



A variety of resources exist to support our common goal of increasing HPV vaccination rates.

- [Ways for Providers to Increase HPV Rates](#)
- [Adolescent #HowIRecommend Vaccination Video Series | CDC](#)
- [Reasons to Get HPV Vaccine | CDC](#)
- [HPV: Information For Healthcare Professionals | CDC](#)
- [Strategies for Improving HPV Vaccination Rates](#)

NIRSEVIMAB SUPPLY INCREASING

Given the recent increase in nirsevimab supply and the [manufacturers' plan to release an additional 230,000 doses in January](#), the Centers for Disease Control and Prevention (CDC) advises healthcare providers to return to recommendations put forward by CDC and the ACIP on use of nirsevimab in young children. Infants and children recommended to receive nirsevimab should be immunized as quickly as possible.

Recommendations for Healthcare Providers:

- In the setting of increasing supply, healthcare providers should administer a single dose of [nirsevimab](#) to all infants aged less than 8 months, as well as children aged 8 through 19 months at [increased risk](#).
 - Although supply of nirsevimab is expected to increase, available supply may continue to vary locally and by healthcare facility. For healthcare providers who continue to have limited supply, nirsevimab should be prioritized to protect infants at the highest risk for severe RSV disease using the following principles: first by [high-risk conditions](#) and then by age, prioritizing the youngest infants first.
 - Neither RSV vaccine (Pfizer Abrysvo, GSK Arexvy) is approved for use in infants or young children. Healthcare providers should take care to use the correct product for the correct population.
- [Pregnant people 32 through 36 weeks gestation should receive RSV vaccination](#) through January.
 - Pfizer Abrysvo is the only RSV vaccine recommended for use in pregnant people. GSK Arexvy is not recommended for use in pregnant people.
- Administration of both nirsevimab and RSV vaccination for pregnant people is not needed to protect most infants.

BECOME A VFC PROVIDER


The Vaccines for Children (VFC) Program helps provide vaccines to children whose parents or guardians may not be able to afford them. This helps ensure that all children have a better chance of getting their recommended vaccinations on time. Vaccines available through the VFC Program are those recommended by the Advisory Committee on Immunization Practices (ACIP). A child is eligible for the VFC Program if he or she is younger than 19 years of age and is one of the following: Medicaid-eligible, Uninsured, Underinsured, American Indian or Alaska Native.

Contact our Immunization Nurse Educators to find out more at 269-945-5619.




Vaccines for Children

Protecting America's children every day


The Vaccines for Children (VFC) program helps ensure that all children have a better chance of getting their recommended vaccines. VFC has helped prevent disease and save lives.



CDC estimates that vaccination of children born between 1994 and 2021 will:

- prevent **472 million** illnesses (29.8 million hospitalizations) 
- help avoid **1,052,000** deaths 
- save nearly **\$2.2 trillion** in total societal costs (that includes \$479 billion in direct costs) 

more than the current population of the entire U.S.A.
greater than the population of Seattle, WA
more than \$5,000 for each American

 U.S. Department of Health and Human Services
Center for Disease Control and Prevention

www.cdc.gov/vaccines/vfcprogram/

UPCOMING EVENTS

MCIR Training Opportunities for Immunizing Providers

- [2024 MCIR Virtual Training Schedule](#)

RESOURCES

MCIR Help Desk Contact Information:

- Email: MDHHS-MCIRHelp@michigan.gov
- Phone: 888-243-6652
- Fax: 517-763-0370
- Hours: Monday - Friday 8:30 AM – 4:30 PM

Barry-Eaton District Health Department
 Phone: (517) 541-2641 Fax: (517) 541-2666